These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17519905)

  • 1. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate.
    Berndorff D; Borkowski S; Sieger S; Rother A; Friebe M; Viti F; Hilger CS; Cyr JE; Dinkelborg LM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7053s-7063s. PubMed ID: 16203802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
    Tijink BM; Perk LR; Budde M; Stigter-van Walsum M; Visser GW; Kloet RW; Dinkelborg LM; Leemans CR; Neri D; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1235-44. PubMed ID: 19259661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.
    Czabanka M; Parmaksiz G; Bayerl SH; Nieminen M; Trachsel E; Menssen HD; Erber R; Neri D; Vajkoczy P
    Eur J Cancer; 2011 May; 47(8):1276-84. PubMed ID: 21396810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma.
    Rajkumar VS; Boxer G; Robson M; Muddle J; Papastavrou Y; Pedley RB
    Tumour Biol; 2012 Dec; 33(6):2019-29. PubMed ID: 22833213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas.
    El Emir E; Qureshi U; Dearling JL; Boxer GM; Clatworthy I; Folarin AA; Robson MP; Nagl S; Konerding MA; Pedley RB
    Cancer Res; 2007 Dec; 67(24):11896-905. PubMed ID: 18089820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19).
    Spaeth N; Wyss MT; Pahnke J; Biollaz G; Trachsel E; Drandarov K; Treyer V; Weber B; Neri D; Buck A
    Nucl Med Biol; 2006 Jul; 33(5):661-6. PubMed ID: 16843841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.
    Borsi L; Balza E; Bestagno M; Castellani P; Carnemolla B; Biro A; Leprini A; Sepulveda J; Burrone O; Neri D; Zardi L
    Int J Cancer; 2002 Nov; 102(1):75-85. PubMed ID: 12353237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
    Antoniw P; Farnsworth AP; Turner A; Haines AM; Mountain A; Mackintosh J; Shochat D; Humm J; Welt S; Old LJ; Yarranton GT; King DJ
    Br J Cancer; 1996 Aug; 74(4):513-24. PubMed ID: 8761364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin.
    Rossin R; Berndorff D; Friebe M; Dinkelborg LM; Welch MJ
    J Nucl Med; 2007 Jul; 48(7):1172-9. PubMed ID: 17574989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin.
    Demartis S; Tarli L; Borsi L; Zardi L; Neri D
    Eur J Nucl Med; 2001 Apr; 28(4):534-9. PubMed ID: 11357506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
    Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
    J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy.
    Fidarova EF; El-Emir E; Boxer GM; Qureshi U; Dearling JL; Robson MP; Begent RH; Trott KR; Pedley RB
    Clin Cancer Res; 2008 May; 14(9):2639-46. PubMed ID: 18451227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Dearling J; Bhatia J; Begent RH
    Int J Radiat Biol; 2001 Apr; 77(4):507-17. PubMed ID: 11304442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
    Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.